All News
Methotrexate in OA (10.20.2023)
Dr. Jack Cush discusses the news, journal articles and regulatory actions. This week we discuss JAKne, DLE and SLE and more.
Read Article
FDA Approves Bimekizumab for Plaque Psoriasis
UCB announced today that the US Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx)) for the treatment of moderate to severe plaque psoriasis in adults who needing systemic therapy or phototherapy.
Read Article
PMR and Palindromic Rheumatism Similarities
I'd like to discuss the similarities between polymyalgia rheumatica and palindromic rheumatism. And in doing that, highlight how these similarities help us understand the relationship between polymyalgia rheumatica and rheumatoid arthritis. Perhaps not everybody watching this will be very familiar with palindromic rheumatism. It is considered uncommon, but every rheumatologist sees it in their practice.
Read Article
Check out my other podcast - the Miracle Larry Podcast. Miracle Larry gave the keynote lecture at RNL2023. A podcast focused on his amazing story. Follow us @Miracle_LarryK. We’d appreciate the support!
https://t.co/6zi2D7hdGJ
Links:
Dr. John Cush RheumNow ( View Tweet)
What Goes Wrong with the Immune System in #PMR?
https://t.co/3DDFXBOfaL https://t.co/WNiWpokP4q
Dr. John Cush RheumNow ( View Tweet)
Using Methotrexate in #PMR
Where in other inflammatory rheumatic disorders, such as RA and PsA, early initiation of MTX is common practice, this is not the case in PMR. Treatment of PMR is still largely based on GC.
https://t.co/pQtmYvF2NS https://t.co/wJTpFPqmlw
Dr. John Cush RheumNow ( View Tweet)
#PMR and Palindromic Rheumatism Similarities
https://t.co/uJ4hJSA0hL https://t.co/rFINkKZh7l
Dr. John Cush RheumNow ( View Tweet)
Check out the latest therapeutic update for axSpA in this video series dedicated to creating a better understanding of treatment goals.https://t.co/VTQI0SzHpO https://t.co/H3yBcnUvwu
Dr. John Cush RheumNow ( View Tweet)
2023 EULAR Lupus Management Recommendations
EULAR has published updated recommendations for the management of systemic lupus erythematosus (SLE) based on new evidence and expert opinion - formulationg five overarching principles and 13 recommendations.
https://t.co/Fzh8F33u3U https://t.co/2baAVsm8Bo
Dr. John Cush RheumNow ( View Tweet)
IL-2 receptor (sCD25) levels as a biomarker of RA-ILD? Study of 294 RA pts (56 w/ ILD) & 58 healthy controls (HCs) (ILD confirmed by HRCT). sCD25 sensitivity 51% & specificity 77%,; it elevated in RA-ILD subtypes (UIP, NSIP); but didnt correlate w/ HRCT https://t.co/1gJ635tu8a https://t.co/aYamfJwJi2
Dr. John Cush RheumNow ( View Tweet)
JAKne? Systematic review &meta-analysis (25 studies, 10 839 pts), JAK inhibitor use was associated with an elevated odds of acne (OR 3-5 for UPA, TOFA, BARI, Deucra; but higher for abrocitinib (OR 13.5). Seen in Derm pts but hardly at all in Rheum pts https://t.co/XdHmARnxpu https://t.co/N7Bm5GIgjd
Dr. John Cush RheumNow ( View Tweet)
RHEUM Survey: In Newly Dx #PMR patients, How many do you do imaging for GCA vascular involvement?
Dr. John Cush RheumNow ( View Tweet)
Looks like #PMR - But is it?
Patients referred to rheumatologists for suspected PMR - but is it? And what's the role of imaging to help make the diagnosis?
https://t.co/oinfFXE978 https://t.co/4aAHrYbjZD
Dr. John Cush RheumNow ( View Tweet)
Could Methotrexate Work in Hand Osteoarthritis?
Lancet reports the results of the METHODS study from Australia where hand osteoarthritis (HOA) patients benefitted from 6 months of methotrexate (MTX) - as long as there was MRI synovitis!
https://t.co/GhVB7WzJLQ https://t.co/Lt0pvm3RCW
Dr. John Cush RheumNow ( View Tweet)
12.3 million Americans over 50 have osteoporosis; 47 million have osteopenia. W/ OP Fx the risk of repeat Fx is highest in 1st 6 mos, yet 8% of Medicare pts w/ Fx have a diagnostic bone density scan (less in African Americans 5%) https://t.co/2mogEEk3tq https://t.co/9tjwXg0WzZ https://t.co/ruLnjm4kXr
Links:
Dr. John Cush RheumNow ( View Tweet)
Tuesday Nite Rheumatology webinar on the use of steroid-sparing drugs in patients with #PMR.
Featuring Panelists: Drs. David Liew, Robert Spiera, Sarah Mackie, Anisha Dua
Moderator: Dr. Sebastian Sattui
https://t.co/HDXCG1bq2m https://t.co/95vfTnXtNP
Dr. John Cush RheumNow ( View Tweet)
Tocilizumab Use in #GCA. In 10 yrs, 114 GCA pts started on TCZ after mean 4.5 mos & Rx for 2.3 yrs. GCA Relapse rates:
- before TCZ 0.84/PY
- on TCZ 0.28/PY (P<0.001)
- post TCZ D/C 0.64/PY
52 pts D/C TCZ after 16.8 mos & 27 (52%) relapsed after 8.4 mo https://t.co/D3INiMdC4U https://t.co/aD2rijR6xd
Dr. John Cush RheumNow ( View Tweet)
Sleep problems in SpA & PsA? Study of 201 pts shows 43% of axSpA and 47% of PsA pts reported sleep problems. In both poor sleep assoc w/ dz activity. In axSpa it signif assoc w/ Dz activity (OR 8.45),biologic use (OR .24), & CRP levels (OR .16) https://t.co/9TEUOODO1P https://t.co/5IhVmOpTCB
Dr. John Cush RheumNow ( View Tweet)
Anifrolumab was studied in 7 adolescents w/ resistant #DLE (discoid); given 6 monthly IV doses. All had signif decreases in skin CLASI-A scores (72%) at 1 month (P =.01), sustained at 6-mo F/U. SLEDAI-2K score also decr by 7 pts; 1 had HSV-1 reactivation https://t.co/Nc0IN1Rsao https://t.co/XeAB99YZMF
Dr. John Cush RheumNow ( View Tweet)
Bimekizumab (Bimelex), a dual IL-17A/F inhibitor, is FDA approved for u Treatment of Adults with Moderate to Severe Plaque Psoriasis https://t.co/IeobNWcM94 https://t.co/OMbhVwFCCt
Dr. John Cush RheumNow ( View Tweet)